Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4

Michiyo Saimura, Eishi Nagai, Kazuhiro Mizumoto, Naoki Maehara, Yohji A. Minamishima, Mitsuo Katano, Kunio Matsumoto, Toshikazu Nakamura, Masao Tanaka

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

NK4, composed of the N-terminal hairpin and subsequent four-kringle domains of hepatocyte growth factor (HGF), acts not only as a competitive antagonist of HGF but also as an inhibitor of angiogenesis. By studying the antitumor effect of NK4, we evaluated the potential of gene therapy with NK4 as a treatment for pancreatic cancer. Expression vector pcDNA3-NK4 containing NK4 cDNA was used to transfect human pancreatic cancer cell line SUIT-2. Although the established NK4 transfectant continuously expressed NK4 protein, the expression was shown by migration assay to be insufficient to antagonize HGF in vitro. Proliferation of the NK4 transfectant did not differ significantly from that of a mock transfectant. In vivo, we used models of orthotopic implantation and liver metastasis to transplant NK4-transfected clone or mock-transfected clone into nude mice. Cell proliferation in vivo, evaluated by immunohistochemical staining of proliferating cell nuclear antigen, did not differ between NK4 and mock transfectants, and this was also the finding in the in vitro assay. However, the NK4-transfected clone showed significant inhibition of tumor progression in both the orthotopic implantation and liver metastasis models. The number of vessels within tumors was significantly decreased, and the apoptotic tumor cells were increased in number. The results of these experiments show that genetic modification of tumor cells with NK4 cDNA yields a significant antitumor effect and that this effect is mainly obtained by NK4's function as an angiogenesis inhibitor rather than as an HGF antagonist. We conclude that the potent angiogenesis inhibitor NK4 may be a promising molecule for gene therapy of pancreatic cancer.

Original languageEnglish
Pages (from-to)3243-3249
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number10
Publication statusPublished - 2002 Oct 1

Fingerprint

Hepatocyte Growth Factor
Pancreatic Neoplasms
Angiogenesis Inhibitors
Clone Cells
Genetic Therapy
Neoplasms
Complementary DNA
Kringles
Neoplasm Metastasis
Liver
Proliferating Cell Nuclear Antigen
Nude Mice
Cell Proliferation
Staining and Labeling
Transplants
Cell Line
Proteins
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Saimura, M., Nagai, E., Mizumoto, K., Maehara, N., Minamishima, Y. A., Katano, M., ... Tanaka, M. (2002). Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clinical Cancer Research, 8(10), 3243-3249.

Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. / Saimura, Michiyo; Nagai, Eishi; Mizumoto, Kazuhiro; Maehara, Naoki; Minamishima, Yohji A.; Katano, Mitsuo; Matsumoto, Kunio; Nakamura, Toshikazu; Tanaka, Masao.

In: Clinical Cancer Research, Vol. 8, No. 10, 01.10.2002, p. 3243-3249.

Research output: Contribution to journalArticle

Saimura, M, Nagai, E, Mizumoto, K, Maehara, N, Minamishima, YA, Katano, M, Matsumoto, K, Nakamura, T & Tanaka, M 2002, 'Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4', Clinical Cancer Research, vol. 8, no. 10, pp. 3243-3249.
Saimura M, Nagai E, Mizumoto K, Maehara N, Minamishima YA, Katano M et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clinical Cancer Research. 2002 Oct 1;8(10):3243-3249.
Saimura, Michiyo ; Nagai, Eishi ; Mizumoto, Kazuhiro ; Maehara, Naoki ; Minamishima, Yohji A. ; Katano, Mitsuo ; Matsumoto, Kunio ; Nakamura, Toshikazu ; Tanaka, Masao. / Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 10. pp. 3243-3249.
@article{2a41ab2fcc954d7787f6d4f702a33765,
title = "Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4",
abstract = "NK4, composed of the N-terminal hairpin and subsequent four-kringle domains of hepatocyte growth factor (HGF), acts not only as a competitive antagonist of HGF but also as an inhibitor of angiogenesis. By studying the antitumor effect of NK4, we evaluated the potential of gene therapy with NK4 as a treatment for pancreatic cancer. Expression vector pcDNA3-NK4 containing NK4 cDNA was used to transfect human pancreatic cancer cell line SUIT-2. Although the established NK4 transfectant continuously expressed NK4 protein, the expression was shown by migration assay to be insufficient to antagonize HGF in vitro. Proliferation of the NK4 transfectant did not differ significantly from that of a mock transfectant. In vivo, we used models of orthotopic implantation and liver metastasis to transplant NK4-transfected clone or mock-transfected clone into nude mice. Cell proliferation in vivo, evaluated by immunohistochemical staining of proliferating cell nuclear antigen, did not differ between NK4 and mock transfectants, and this was also the finding in the in vitro assay. However, the NK4-transfected clone showed significant inhibition of tumor progression in both the orthotopic implantation and liver metastasis models. The number of vessels within tumors was significantly decreased, and the apoptotic tumor cells were increased in number. The results of these experiments show that genetic modification of tumor cells with NK4 cDNA yields a significant antitumor effect and that this effect is mainly obtained by NK4's function as an angiogenesis inhibitor rather than as an HGF antagonist. We conclude that the potent angiogenesis inhibitor NK4 may be a promising molecule for gene therapy of pancreatic cancer.",
author = "Michiyo Saimura and Eishi Nagai and Kazuhiro Mizumoto and Naoki Maehara and Minamishima, {Yohji A.} and Mitsuo Katano and Kunio Matsumoto and Toshikazu Nakamura and Masao Tanaka",
year = "2002",
month = "10",
day = "1",
language = "English",
volume = "8",
pages = "3243--3249",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4

AU - Saimura, Michiyo

AU - Nagai, Eishi

AU - Mizumoto, Kazuhiro

AU - Maehara, Naoki

AU - Minamishima, Yohji A.

AU - Katano, Mitsuo

AU - Matsumoto, Kunio

AU - Nakamura, Toshikazu

AU - Tanaka, Masao

PY - 2002/10/1

Y1 - 2002/10/1

N2 - NK4, composed of the N-terminal hairpin and subsequent four-kringle domains of hepatocyte growth factor (HGF), acts not only as a competitive antagonist of HGF but also as an inhibitor of angiogenesis. By studying the antitumor effect of NK4, we evaluated the potential of gene therapy with NK4 as a treatment for pancreatic cancer. Expression vector pcDNA3-NK4 containing NK4 cDNA was used to transfect human pancreatic cancer cell line SUIT-2. Although the established NK4 transfectant continuously expressed NK4 protein, the expression was shown by migration assay to be insufficient to antagonize HGF in vitro. Proliferation of the NK4 transfectant did not differ significantly from that of a mock transfectant. In vivo, we used models of orthotopic implantation and liver metastasis to transplant NK4-transfected clone or mock-transfected clone into nude mice. Cell proliferation in vivo, evaluated by immunohistochemical staining of proliferating cell nuclear antigen, did not differ between NK4 and mock transfectants, and this was also the finding in the in vitro assay. However, the NK4-transfected clone showed significant inhibition of tumor progression in both the orthotopic implantation and liver metastasis models. The number of vessels within tumors was significantly decreased, and the apoptotic tumor cells were increased in number. The results of these experiments show that genetic modification of tumor cells with NK4 cDNA yields a significant antitumor effect and that this effect is mainly obtained by NK4's function as an angiogenesis inhibitor rather than as an HGF antagonist. We conclude that the potent angiogenesis inhibitor NK4 may be a promising molecule for gene therapy of pancreatic cancer.

AB - NK4, composed of the N-terminal hairpin and subsequent four-kringle domains of hepatocyte growth factor (HGF), acts not only as a competitive antagonist of HGF but also as an inhibitor of angiogenesis. By studying the antitumor effect of NK4, we evaluated the potential of gene therapy with NK4 as a treatment for pancreatic cancer. Expression vector pcDNA3-NK4 containing NK4 cDNA was used to transfect human pancreatic cancer cell line SUIT-2. Although the established NK4 transfectant continuously expressed NK4 protein, the expression was shown by migration assay to be insufficient to antagonize HGF in vitro. Proliferation of the NK4 transfectant did not differ significantly from that of a mock transfectant. In vivo, we used models of orthotopic implantation and liver metastasis to transplant NK4-transfected clone or mock-transfected clone into nude mice. Cell proliferation in vivo, evaluated by immunohistochemical staining of proliferating cell nuclear antigen, did not differ between NK4 and mock transfectants, and this was also the finding in the in vitro assay. However, the NK4-transfected clone showed significant inhibition of tumor progression in both the orthotopic implantation and liver metastasis models. The number of vessels within tumors was significantly decreased, and the apoptotic tumor cells were increased in number. The results of these experiments show that genetic modification of tumor cells with NK4 cDNA yields a significant antitumor effect and that this effect is mainly obtained by NK4's function as an angiogenesis inhibitor rather than as an HGF antagonist. We conclude that the potent angiogenesis inhibitor NK4 may be a promising molecule for gene therapy of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036796020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036796020&partnerID=8YFLogxK

M3 - Article

C2 - 12374695

AN - SCOPUS:0036796020

VL - 8

SP - 3243

EP - 3249

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -